StockDuty ← Dashboard Oct 15, 2026 04:01 PM ET
SignalCorporate

Recursion Announces $200 Million Oversubscribed Follow-On Offering, Clinical Data Updates, and Partnership Milestone

$200M oversubscribed offering plus clinical data and partnership milestone signal multiple catalysts.

What happened: Recursion announced a $200 million oversubscribed follow-on offering with healthcare investors, plus clinical updates for REC-4881 in FAP and REC-1245, and a Sanofi partnership milestone. Key numbers: $200 million offering. Why it matters: The financing and data support Recursion's pipeline momentum, with a registrational trial targeted for 2H 2027 pending FDA discussions and Sanofi optioning a development candidate from their collaboration. Market: +1.9% today ($16.13), 0.1x vol — as of 15:47 UTC
Recursion announced a $200 million oversubscribed follow-on offering with healthcare investors, plus clinical updates for REC-4881 in FAP and REC-1245, and a Sanofi partnership milestone.
The financing and data support Recursion's pipeline momentum, with a registrational trial targeted for 2H 2027 pending FDA discussions and Sanofi optioning a development candidate from their collaboration. Market: +1.9% today ($16.13), 0.1x vol — as of 15:47 UTC
Sources